Business Standard

Friday, December 20, 2024 | 11:11 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Why a vaccine that stops coronavirus won't be enough to end the pandemic

A vaccine's ability to forestall a disease is also how vaccine developers typically design - and how regulators typically evaluate - Phase 3 clinical trials for vaccine candidates

Pfizer, BioNTech Covid-19 vaccine on track for regulatory review in October
Premium

Focusing on how to block the coronavirus’s transmission is a much more efficient approach.

Adam Finn and Richard Malley | NYT
Not long after the new coronavirus first surfaced last December, an ambitious prediction was made: A vaccine would be available within 12 to 18 months, and it would stop the pandemic.

Despite serious challenges — how to mass manufacture, supply and deliver a vaccine worldwide — the first prong of that wish could well be fulfilled. Eight vaccine candidates are undergoing large-scale efficacy tests, so-called Phase 3 trials, and results are expected by the end of this year or early 2021.

But even if one, or more, of those efforts succeeds, a vaccine might not end the pandemic. This is

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in